Furthermore, there is emerging evidence that highlights the critical need for developing specific inhibitors of vascular KATP channels for the treatment of diverse vascular-related disorders, such as Cantu syndrome, a rare genetic disease resulting from gain-of-function mutations in KCNJ8 or ABCC9 [22–27], patent ductus arteriosus [28,29], and sepsis [30]. Here, KCNJ8 is linked to hypertrichotic osteochondrodysplasia Cantu type.